Tab. 1.
BLOCK/CONC MODEL PEAK VELOCITY [eq. 1] (n=60) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Group | CPKV Average 1/unit | CPKV ±SD 1/unit | CPKV Range 1/unit | CPKV >0/<0/~0 # | t-value | Prob | R2 Average | R2 ±SD | R2 Range |
Placebo (Blocks) | −0.002 | 0.015 | −0.047 0.028 |
14/19/27 | −1.2 | 0.2 | 0.76 | 0.13 | 0.36 0.97 |
Propof. (μg/ml) | −0.33* | 0.24 | −0.91 0.22 |
1/56/3 | −10.3 | 1×10−14 | 0.72 | 0.18 | 0.27 0.97 |
Midaz. (ng/ml) | −0.0050* | 0.0048 | −0.0199 0.0060 |
0/49/11 | −8.0 | 6×10−11 | 0.65 | 0.18 | 0.27 0.93 |
Dexmed. (ng/ml) | −0.21* | 0.33 | −0.96 0.79 |
6/39/15 | −4.9 | 8×10−6 | 0.68 | 0.16 | 0.38 0.94 |
BLOCK/CONC MODEL DURATION [eq. 2] (n=60) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Group | CDUR Average 1/unit | CDUR ±SD 1/unit | CDUR Range 1/unit | CDUR >0/<0/~0 # | t-value | Prob | R2 Average | R2 ±SD | R2 Range |
Placebo (Blocks) | 0.004 | 0.020 | −0.050 0.048 |
25/8/27 | 1.7 | 0.09 | 0.62 | 0.28 | 0.04 0.98 |
Propof. (μg/ml) | 1.82* | 4.10 | −0.44 25.71 |
49/2/9 | 3.4 | 1×10−3 | 0.50 | 0.25 | 0.05 0.89 |
Midaz. (ng/ml) | 0.029* | 0.041 | −0.005 0.186 |
54/0/6 | 5.4 | 1×10−6 | 0.42 | 0.20 | 0.09 0.86 |
Dexmed. (ng/ml) | 1.08* | 1.27 | −0.17 6.48 |
45/2/13 | 6.6 | 1×10−8 | 0.44 | 0.21 | 0.07 0.86 |
BLOCK/CONC MODEL RECIPROCAL OF LATENCY [eq. 3] (n=60) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Group | CRLAT Average 1/unit | CRLAT ±SD 1/unit | CRLAT Range 1/unit | CRLAT >0/<0/~0 # | t-value | Prob | R2 Average | R2 ±SD | R2 Range |
Placebo (Blocks) | 0.015* | 0.015 | −0.020 0.054 |
41/3/16 | 7.9 | 8×10−11 | 0.14 | 0.10 | 0.00 0.41 |
Propof. (μg/ml) | −0.27* | 0.21 | −0.63 0.21 |
4/46/10 | −9.8 | 6×10−14 | 0.23 | 0.16 | 0.00 0.63 |
Midaz. (ng/ml) | −0.0041* | 0.0040 | −0.0170 0.0038 |
0/46/14 | −8.0 | 5×10−11 | 0.16 | 0.11 | 0.00 0.45 |
Dexmed. (ng/ml) | −0.03 | 0.27 | −0.86 0.78 |
12/21/27 | −0.9 | 0.3 | 0.12 | 0.09 | 0.00 0.45 |
BLOCK/CONC MODEL GAIN PRIMARY SACCADE [eq. 4] (n=60) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Group | CGAIN Average 1/unit | CGAIN ±SD 1/unit | CGAIN Range 1/unit | CGAIN >0/<0/~0 # | t-value | Prob | R2 Average | R2 ±SD | R2 Range |
Placebo (Blocks) | 0.006* | 0.015 | −0.026 0.049 |
25/8/27 | 3.1 | 0.003 | 0.21 | 0.15 | 0.00 0.62 |
Propof. (μg/ml) | −0.18* | 0.20 | −0.79 0.18 |
4/40/16 | −6.9 | 4×10−9 | 0.23 | 0.17 | 0.00 0.76 |
Midaz. (ng/ml) | −0.0045* | 0.0036 | −0.0124 0.0086 |
1/50/9 | −9.7 | 8×10−14 | 0.27 | 0.16 | 0.00 0.70 |
Dexmed. (ng/ml) | 0.04 | 0.25 | −0.43 0.62 |
14/14/32 | 1.1 | 0.3 | 0.18 | 0.14 | 0.01 0.55 |
“C[] Average”: average of the parameter C from eqs. [1–4] (±SD and range). The unit is reported in parenthesis in the first column below the group label. An asterisk near the average indicates that the value was significantly different from 0, using a one-sample t-test with H0=0 (p<0.05, n=60). The t-value and probability of these tests are reported in columns “t-value” and “Prob”. The “>0/<0/~0” columns report the number of >0 significances, the number of <0 significances, and the number of no significances (~0) of the C values at the subject level. Last three columns: average, ±SD and range of the R2 of the model fits.